Searched for: person:priced03
in-biosketch:true
Modification of a parent-report sleep scale for individuals with CDKL5 deficiency disorder: a psychometric study
Saldaris, Jacinta M; Demarest, Scott; Jacoby, Peter; Olson, Heather E; Maski, Kiran; Pestana-Knight, Elia; Price, Dana; Rajaraman, Rajsekar; Suter, Bernhard; Weisenberg, Judith; Leonard, Helen; Marsh, Eric D; Benke, Tim A; Downs, Jenny
STUDY OBJECTIVES/OBJECTIVE:Sleep difficulties are common in CDKL5 deficiency disorder (CDD), a developmental and epileptic encephalopathy (DEE). This study evaluated the factor structure of the Disorders of Initiating and Maintaining Sleep (DIMS), Disorders of Excessive Daytime Somnolence (DOES) and Sleep Breathing Disorders (SBD) domains of the Sleep Disturbance Scale for Children (SDSC) for CDD. METHODS:A cross-sectional psychometric study design was used. Data were collected for 125 individuals aged 3 years or older who attended a US Centers of Excellence clinic or registered with the International CDKL5 Disorder Database. RESULTS:The median age was 10.3 years (range 3.2 - 40.7 years) and 105 (84%) were female. Two of the three SBD items related were not observed by most respondents and analysis was restricted to the DIMS and DOES domains. Using all items in the initial confirmatory factor analysis, two items in the DIMS domain and one item in the DOES domain loaded poorly. After deleting these items and repeating the analysis, item loading (0.524-0.814) and internal consistency (DIMS: 0.78, DOES: 0.76) statistics were good. The square of the inter-domain correlation coefficient was 0.17, less than Average Variance Extracted values for both domains and indicating good discriminant validity. The Tucker-Lewis and Comparative Fit indices were slightly lower than the threshold of >0.9 for establishing goodness of fit. CONCLUSIONS:The modified DIMS and DOES domains from the SDSC could be suitable clinical outcome assessments of insomnia and related impairments in CDD and potentially other DEE conditions.
PMID: 38963064
ISSN: 1550-9397
CID: 5732812
Psychometric evaluation of clinician- and caregiver-reported clinical severity assessments for individuals with CDKL5 deficiency disorder
Saldaris, Jacinta M; Jacoby, Peter; Downs, Jenny; Marsh, Eric D; Leonard, Helen; Pestana-Knight, Elia; Rajaraman, Rajsekar; Weisenberg, Judith; Suter, Bernhard; Olson, Heather E; Price, Dana; Hong, William; Prange, Erin; Benke, Tim A; Demarest, Scott
OBJECTIVE:The CDKL5 Clinical Severity Assessment (CCSA) is a comprehensive, content-validated measurement tool capturing the diverse challenges of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), a genetically caused developmental epileptic encephalopathy (DEE). The CCSA is divided into clinician-reported (CCSA-Clinician) and caregiver-reported (CCSA-Caregiver) assessments. The aim of this study was to evaluate the factor structure of these measures through confirmatory factor analysis (CFA) and evaluate their validity and reliability. METHODS:Participants were recruited from the International CDKL5 Clinical Research Network to take part in an in-clinic CCSA-Clinician evaluation (n = 148) and/or complete the CCSA-Caregiver questionnaire (n = 198). CFA was used to determine domains, and factor loadings and validity were assessed. For the CCSA-Clinician, inter-rater reliability was assessed by nine CDD experienced clinicians via 14 pre-recorded evaluations. Eight clinicians re-viewed and re-scored the videos after 4 weeks to evaluate intra-rater reliability. The CCSA-Caregiver was completed on a second occasion by 34 caregivers after 2-4 weeks to assess test-retest reliability. RESULTS:CFA resulted in three domains for the CCSA-Clinician (motor and movement, communication, vision) and four domains for the CCSA-Caregiver (seizures, behavior, alertness, feeding), with good item loadings across both measures. Structural statistics, internal consistency, discriminant validity, and reliability were satisfactory for both measures, and scores were consistent between known groups. SIGNIFICANCE/CONCLUSIONS:This study provides strong evidence that the CCSA measures are suitable to assess the clinical severity of individuals with CDD, supporting their use in clinical trials. Further evaluation of responsiveness to change in a longitudinal assessment is planned. Use may also be appropriate in similar DEEs but would require validation in those populations.
PMCID:11495992
PMID: 39190322
ISSN: 1528-1167
CID: 5729662
Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity
Francoeur, Conall; Alcamo, Alicia M; Robertson, Courtney L; Wainwright, Mark S; Roa, Juan D; Lovett, Marlina E; Stulce, Casey; Yacoub, Mais; Potera, Renee M; Zivick, Elizabeth; Holloway, Adrian; Nagpal, Ashish; Wellnitz, Kari; Even, Katelyn M; Brunow de Carvalho, Werther; Rodriguez, Isadora S; Schwartz, Stephanie P; Walker, Tracie C; Campos-Miño, Santiago; Dervan, Leslie A; Geneslaw, Andrew S; Sewell, Taylor B; Pryce, Patrice; Silver, Wendy G; Lin, Jieru E; Vargas, Wendy S; Topjian, Alexis; McGuire, Jennifer L; DomÃnguez Rojas, Jesus Angel; Tasayco-Muñoz, Jaime; Hong, Sue J; Muller, William J; Doerfler, Matthew; Williams, Cydni N; Drury, Kurt; Bhagat, Dhristie; Nelson, Aaron; Price, Dana; Dapul, Heda; Santos, Laura; Kahoud, Robert; Appavu, Brian; Guilliams, Kristin P; Agner, Shannon C; Walson, Karen H; Rasmussen, Lindsey; Pal, Ria; Janas, Anna; Ferrazzano, Peter; Farias-Moeller, Raquel; Snooks, Kellie C; Chang, Chung-Chou H; Iolster, Tomás; Erklauer, Jennifer C; Jorro Baron, Facundo; Wassmer, Evangeline; Yoong, Michael; Jardine, Michelle; Mohammad, Zoha; Deep, Akash; Kendirli, Tanil; Lidsky, Karen; Dallefeld, Samantha; Flockton, Helen; Agrawal, Shruti; Siruguppa, Krishna Sumanth; Waak, Michaela; Gutiérrez-Mata, Alfonso; Butt, Warwick; Bogantes-Ledezma, Sixto; Sevilla-Acosta, Fabricio; Umaña-Calderón, Andres; Ulate-Campos, Adriana; Yock-Corrales, Adriana; Talisa, Victor Brodzik; Kanthimathinathan, Hari Krishnan; Schober, Michelle E; Fink, Ericka L; ,
IMPORTANCE/UNASSIGNED:Neurological manifestations during acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity. OBJECTIVE/UNASSIGNED:To assess the association of severe neurological manifestations during a SARS-CoV-2-related hospital admission with new neurocognitive or functional morbidities at discharge. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021. EXPOSURE/UNASSIGNED:Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke. MAIN OUTCOMES AND MEASURES/UNASSIGNED:The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2-related condition. RESULTS/UNASSIGNED:Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P < .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations (P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge. CONCLUSIONS AND RELEVANCE/UNASSIGNED:The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
PMID: 38857050
ISSN: 2574-3805
CID: 5668852
Adapting a measure of gross motor skills for individuals with CDKL5 deficiency disorder: A psychometric study
Saldaris, J M; Jacoby, P; Marsh, E D; Suter, B; Leonard, H; Olson, H E; Rajaraman, R; Pestana-Knight, E; Weisenberg, J; Price, D; Drummond, C; Benke, T A; Demarest, S; Downs, J
PURPOSE/OBJECTIVE:Validated measures capable of demonstrating meaningful interventional change in the CDKL5 deficiency disorder (CDD) are lacking. The study objective was to modify the Rett Syndrome Gross Motor Scale (RSGMS) and evaluate its psychometric properties for individuals with CDD. METHODS:Item and scoring categories of the RSGMS were modified. Caregivers registered with the International CDKL5 Clinical Research Network uploaded motor videos filmed at home to a protected server and completed a feedback questionnaire (n = 70). Rasch (n = 137), known groups (n = 109), and intra- and inter-rater reliability analyses (n = 50) were conducted. RESULTS:The age of individuals with CDD ranged from 1.5 to 34.1 years. The modified scale, Gross Motor-Complex Disability (GM-CD), comprised 17 items. There were no floor or ceiling effects and inter- and intra-rater reliability were good. Rasch analysis demonstrated that the items encompassed a large range of performance difficulty, although there was some item redundancy and some disordered categories. One item, Prone Head Position, was a poor fit. Caregiver-reported acceptability was positive. Scores differed by age and functional abilities. SUMMARY/CONCLUSIONS:GM-CD appears to be a suitable remotely administered measure and psychometrically sound for individuals with CDD. This study provides the foundation to propose the use of GM-CD in CDD clinical trials. Longitudinal evaluation is planned.
PMID: 38237219
ISSN: 1872-6844
CID: 5633842
The development, content and response process validation of a caregiver-reported severity measure for CDKL5 deficiency disorder
Ziniel, Sonja I; Mackie, Alexandra; Saldaris, Jacinta; Leonard, Helen; Jacoby, Peter; Marsh, Eric D; Suter, Bernhard; Pestana-Knight, Elia; Olson, Heather E; Price, Dana; Weisenberg, Judith; Rajaraman, Rajsekar; VanderVeen, Gina; Benke, Tim A; Downs, Jenny; Demarest, Scott
BACKGROUND:CDKL5 Deficiency Disorder (CDD) is a severe X-linked developmental and epileptic encephalopathy. Existing developmental outcome measures have floor effects and cannot capture incremental changes in symptoms. We modified the caregiver portion of a CDD clinical severity assessment (CCSA) and assessed content and response-process validity. METHODS:We conducted cognitive interviews with 15 parent caregivers of 1-39-year-old children with CDD. Caregivers discussed their understanding and concerns regarding appropriateness of both questions and answer options. Item wording and questionnaire structure were adjusted iteratively to ensure questions were understood as intended. RESULTS:The CCSA was refined during three rounds of cognitive interviews into two measures: (1) the CDD Developmental Questionnaire - Caregiver (CDQ-Caregiver) focused on developmental skills, and (2) the CDD Clinical Severity Assessment - Caregiver (CCSA-Caregiver) focused on symptom severity. Branching logic was used to ensure questions were age and skill appropriate. Initial pilot data (n = 11) suggested no floor effects. CONCLUSIONS:This study modified the caregiver portion of the initial CCSA and provided evidence for its content and response process validity.
PMID: 37751639
ISSN: 1872-6844
CID: 5609382
Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C
Fink, Ericka L; Robertson, Courtney L; Wainwright, Mark S; Roa, Juan D; Lovett, Marlina E; Stulce, Casey; Yacoub, Mais; Potera, Renee M; Zivick, Elizabeth; Holloway, Adrian; Nagpal, Ashish; Wellnitz, Kari; Czech, Theresa; Even, Katelyn M; Brunow de Carvalho, Werther; Rodriguez, Isadora Souza; Schwartz, Stephanie P; Walker, Tracie C; Campos-Miño, Santiago; Dervan, Leslie A; Geneslaw, Andrew S; Sewell, Taylor B; Pryce, Patrice; Silver, Wendy G; Lin, Jieru Egeria; Vargas, Wendy S; Topjian, Alexis; Alcamo, Alicia M; McGuire, Jennifer L; DomÃnguez Rojas, Jesus Angel; Muñoz, Jaime Tasayco; Hong, Sue J; Muller, William J; Doerfler, Matthew; Williams, Cydni N; Drury, Kurt; Bhagat, Dhristie; Nelson, Aaron; Price, Dana; Dapul, Heda; Santos, Laura; Kahoud, Robert; Francoeur, Conall; Appavu, Brian; Guilliams, Kristin P; Agner, Shannon C; Walson, Karen H; Rasmussen, Lindsey; Janas, Anna; Ferrazzano, Peter; Farias-Moeller, Raquel; Snooks, Kellie C; Chang, Chung-Chou H; Yun, James; Schober, Michelle E
BACKGROUND:Our objective was to characterize the frequency, early impact, and risk factors for neurological manifestations in hospitalized children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or multisystem inflammatory syndrome in children (MIS-C). METHODS:Multicenter, cross-sectional study of neurological manifestations in children aged <18Â years hospitalized with positive SARS-CoV-2 test or clinical diagnosis of a SARS-CoV-2-related condition between January 2020 and April 2021. Multivariable logistic regression to identify risk factors for neurological manifestations was performed. RESULTS:Of 1493 children, 1278 (86%) were diagnosed with acute SARS-CoV-2 and 215 (14%) with MIS-C. Overall, 44% of the cohort (40% acute SARS-CoV-2 and 66% MIS-C) had at least one neurological manifestation. The most common neurological findings in children with acute SARS-CoV-2 and MIS-C diagnosis were headache (16% and 47%) and acute encephalopathy (15% and 22%), both PÂ <Â 0.05. Children with neurological manifestations were more likely to require intensive care unit (ICU) care (51% vs 22%), PÂ <Â 0.001. In multivariable logistic regression, children with neurological manifestations were older (odds ratio [OR] 1.1 and 95% confidence interval [CI] 1.07 to 1.13) and more likely to have MIS-C versus acute SARS-CoV-2 (OR 2.16, 95% CI 1.45 to 3.24), pre-existing neurological and metabolic conditions (OR 3.48, 95% CI 2.37 to 5.15; and OR 1.65, 95% CI 1.04 to 2.66, respectively), and pharyngeal (OR 1.74, 95% CI 1.16 to 2.64) or abdominal pain (OR 1.43, 95% CI 1.03 to 2.00); all PÂ <Â 0.05. CONCLUSIONS:In this multicenter study, 44% of children hospitalized with SARS-CoV-2-related conditions experienced neurological manifestations, which were associated with ICU admission and pre-existing neurological condition. Posthospital assessment for, and support of, functional impairment and neuroprotective strategies are vitally needed.
PMCID:8713420
PMID: 35066369
ISSN: 1873-5150
CID: 5139372
Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder
Saldaris, Jacinta; Weisenberg, Judith; Pestana-Knight, Elia; Marsh, Eric D; Suter, Bernhard; Rajaraman, Rajsekar; Heidary, Gena; Olson, Heather E; Devinsky, Orrin; Price, Dana; Jacoby, Peter; Leonard, Helen; Benke, Tim A; Demarest, Scott; Downs, Jenny
CDKL5 deficiency disorder (CDD) results in early-onset seizures and severe developmental impairments. A CDD clinical severity assessment (CCSA) was previously developed with clinician and parent-report items to capture information on a range of domains. Consistent with US Food and Drug Administration (FDA) guidelines, content validation is the first step in evaluating the psychometric properties of an outcome measure. The aim of this study was to validate the content of the clinician-reported items in the CCSA (CCSA-Clinician). Eight neurologists leading the USA CDD Center of Excellence clinics were interviewed using the "think aloud" technique to critique 26 clinician-reported items. Common themes were aggregated, and a literature search of related assessments informed item modifications. The clinicians then participated in 2 consensus meetings to review themes and finalize the items. A consensus was achieved for the content of the CCSA-Clinician. Eight of the original items were omitted, 11 items were added, and the remaining 18 items were revised. The final 29 items were classified into 2 domains: functioning and neurologic impairments. This study enabled refinement of the CCSA-Clinician and provided evidence for its content validity. This preliminary validation is essential before field testing and further validation, in order to advance the instrument toward clinical trial readiness.
PMCID:8458223
PMID: 34378447
ISSN: 1708-8283
CID: 5006192
Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder
Devinsky, Orrin; King, LaToya; Schwartz, Danielle; Conway, Erin; Price, Dana
CDKL5 deficiency disorder (CDD) is an X-linked pharmacoresistant neurogenetic disorder characterized by global developmental delays and uncontrolled seizures. Fenfluramine (FFA), an antiseizure medication (ASM) indicated for treating convulsive seizures in Dravet syndrome, was assessed in six patients (five female; 83%) with CDD whose seizures had failed 5-12 ASMs or therapies. Median age at enrollment was 6.5 years (range: 2-26 years). Mean FFA treatment duration was 5.3 months (range: 2-9 months) at 0.4 mg/kg/day (n = 2) or 0.7 mg/kg/day (n = 4; maximum: 26 mg/day). One patient had valproate added for myoclonic seizures. The ASM regimens of all other patients were stable. Among five patients with tonic-clonic seizures, FFA treatment resulted in a median 90% reduction in frequency (range: 86%-100%). Tonic seizure frequency was reduced by 50%-60% in two patients with this seizure type. One patient experienced fewer myoclonic seizures; one patient first developed myoclonic seizures on FFA, which were controlled with valproate. Adverse events were reported in two patients. The patient with added valproate experienced lethargy; one patient had decreased appetite and flatus. No patient developed valvular heart disease or pulmonary arterial hypertension. Our preliminary results suggest that FFA may be a promising ASM for CDD. Randomized clinical trials are warranted.
PMID: 33979451
ISSN: 1528-1167
CID: 4867492
Focal nonmotor versus motor seizures: The impact on diagnostic delay in focal epilepsy
Pellinen, Jacob; Tafuro, Erica; Yang, Annie; Price, Dana; Friedman, Daniel; Holmes, Manisha; Barnard, Sarah; Detyniecki, Kamil; Hegde, Manu; Hixson, John; Haut, Sheryl; Kälviäinen, Reetta; French, Jacqueline
OBJECTIVE:To test the hypothesis that people with focal epilepsy experience diagnostic delays that may be associated with preventable morbidity, particularly when seizures have only nonmotor symptoms, we compared time to diagnosis, injuries, and motor vehicle accidents (MVAs) in people with focal nonmotor versus focal seizures with motor involvement at epilepsy onset. METHODS:This retrospective study analyzed the enrollment data from the Human Epilepsy Project, which enrolled participants between 2012 and 2017 across 34 sites in the USA, Canada, Europe, and Australia, within 4 months of treatment for focal epilepsy. A total of 447 participants were grouped by initial seizure semiology (focal nonmotor or focal with motor involvement) to compare time to diagnosis and prediagnostic injuries including MVAs. RESULTS:Demographic characteristics were similar between groups. There were 246 participants (55%) with nonmotor seizures and 201 participants (45%) with motor seizures at epilepsy onset. Median time to diagnosis from first seizure was 10 times longer in patients with nonmotor seizures compared to motor seizures at onset (PÂ <Â .001). The number and severity of injuries were similar between groups. However, 82.6% of MVAs occurred in patients with undiagnosed nonmotor seizures. SIGNIFICANCE/CONCLUSIONS:This study identifies reasons for delayed diagnosis and consequences of delay in patients with new onset focal epilepsy, highlighting a treatment gap that is particularly significant in patients who experience nonmotor seizures at epilepsy onset.
PMID: 33078409
ISSN: 1528-1167
CID: 4647112
Basics of modern epilepsy classification and terminology
Varnado, Shelley; Price, Dana
BACKGROUND:The terminology and classification of seizures and epilepsy has undergone multiple revisions in the last several decades, which can lead to confusion and miscommunication amongst physicians and researchers. In 2017, the International League Against Epilepsy (ILAE) revised the classification of both seizures and epilepsy types in an effort to use less ambiguous terminology. Over time, definitions for status epilepticus, febrile seizures, and neonatal seizures have also evolved, as has the delineation of various epilepsy syndromes by age. METHODS:Review of the literature for old and new terminology and various epilepsy syndromes was accomplished using the PubMed database system. RESULTS:In the following article, we review old terminology for classifying seizures and epilepsy as compared to the new (2017) ILAE guidelines. We discuss neonatal seizures, status epilepticus, febrile seizures, autoimmune epilepsy and various epilepsy syndromes by age of onset. CONCLUSION/CONCLUSIONS:Adopting a classification system that uses plain language allows for more effective and efficient communication between individuals and across specialties. Definitions of various syndromes and seizure types have evolved over time and are reviewed.
PMID: 33153903
ISSN: 1538-3199
CID: 4668712